Between the negative Phase III news on Oxford BioMedica plc's TroVax and the positive Phase III news on Biovest International Inc.'s BiovaxID, it's been a big month for cancer vaccines. (BioWorld Financial Watch)
Biovest International Inc. said cancer vaccine BiovaxID (personalized anti-idiotype vaccine) met its primary endpoint of significantly improving disease-free survival in a multicenter, randomized, controlled Phase III trial of patients with indolent follicular non-Hodgkin's lymphoma (NHL). (BioWorld Today)
In a deal to be announced Thursday morning, MacroGenics Inc. is bolstering its anticancer antibody pipeline with the acquisition of Raven Biotechnologies Inc. (BioWorld Today)
